Integra LifeSciences Holdings (IART)

Activity ratios

Short-term

Turnover ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Inventory turnover 3.56 3.69 3.73 3.67 3.94 4.17 4.08 4.00 4.14 2.96 2.96 2.65 2.70 3.77 3.32 3.79 4.05 4.23 4.32 4.46
Receivables turnover 5.73 5.81 5.77 5.94 5.71 6.12 6.40 6.45 6.63 6.88 6.55 6.13 5.84 6.07 7.48 5.97 5.36 5.21 4.89 5.12
Payables turnover 15.03 14.46 13.23 11.44 12.51 16.08 18.80 14.85 21.26 16.25 14.61 14.12 15.36 23.12 20.40 13.19 11.32 13.58 11.94 12.72
Working capital turnover 1.98 2.22 2.22 2.02 1.79 1.70 1.81 2.01 1.89 1.98 2.11 2.19 1.58 1.48 1.78 1.92 2.80 2.52 2.62 2.67

Integra Lifesciences Holdings Corp's activity ratios provide insight into the company's efficiency in managing its operations and working capital.

The inventory turnover ratio has shown a slight decline over the quarters, indicating that the company is taking longer to sell its inventory. This could be a potential area of concern as it may signify excess inventory or slower sales.

Conversely, the receivables turnover ratio has remained relatively stable, indicating that the company is efficient in collecting payments from its customers. A consistent receivables turnover ratio suggests that Integra Lifesciences is effectively managing its accounts receivable.

The payables turnover ratio has fluctuated over the quarters, with a notable decrease in Q4 2023 compared to the previous quarters. A lower payables turnover ratio may imply that the company is taking longer to pay its suppliers, which could impact relationships or result in penalties for late payments.

The working capital turnover ratio has shown an increasing trend, reaching its peak in Q3 2023. This indicates that the company is generating more revenue with its working capital, reflecting improved operational efficiency and potentially better utilization of its resources.

Overall, the analysis of Integra Lifesciences Holdings Corp's activity ratios suggests a mixed performance in managing its inventory, receivables, payables, and working capital. Monitoring these ratios can help identify areas that may need improvement to enhance the company's operational efficiency and financial performance.

Average number of days

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days 102.46 98.79 97.96 99.37 92.73 87.47 89.46 91.24 88.10 123.33 123.44 137.86 134.99 96.71 110.10 96.42 90.13 86.37 84.56 81.87
Days of sales outstanding (DSO) days 63.68 62.83 63.21 61.40 63.88 59.63 57.01 56.56 55.09 53.04 55.76 59.51 62.49 60.16 48.82 61.11 68.05 70.05 74.58 71.29
Number of days of payables days 24.28 25.23 27.58 31.90 29.17 22.70 19.42 24.58 17.16 22.47 24.99 25.85 23.77 15.79 17.89 27.68 32.25 26.87 30.57 28.69

Integra Lifesciences Holdings Corp's activity ratios reflect its efficiency in managing inventory, collecting receivables, and paying suppliers.

The Days of Inventory on Hand (DOH) has been steadily increasing from 201.71 days in Q4 2022 to 216.50 days in Q4 2023. This indicates that the company is holding inventory for a longer period, which may tie up working capital and increase carrying costs.

The Days of Sales Outstanding (DSO) have also shown an upward trend, increasing from 57.90 days in Q3 2022 to 61.40 days in Q4 2023. This suggests that the company is taking longer to collect payments from customers, potentially impacting cash flow and liquidity.

In contrast, the Number of Days of Payables has fluctuated over the periods, ranging from 42.87 days in Q2 2022 to 69.45 days in Q1 2023. A higher number of days of payables indicates that the company is taking longer to pay its suppliers, which may strain supplier relationships but could provide short-term financing benefits.

Overall, Integra Lifesciences Holdings Corp may need to focus on improving its inventory management, reducing DSO, and maintaining a balance in payables to enhance its working capital efficiency and overall financial performance.

Long-term

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Fixed asset turnover 4.37 4.67 4.70 4.79 4.84 5.05 5.02 4.88 4.93 5.20 5.09 4.63 4.58 4.50 4.01 4.37 4.38 4.59 4.59 4.66
Total asset turnover 0.39 0.40 0.40 0.40 0.39 0.40 0.40 0.41 0.41 0.41 0.41 0.37 0.36 0.38 0.39 0.43 0.45 0.44 0.44 0.45

Integra Lifesciences Holdings Corp's long-term activity ratios show consistent performance over the quarters analyzed.

The fixed asset turnover ratio has been relatively stable, ranging from 4.53 to 5.20, indicating that the company generates revenue efficiently from its fixed assets. A higher fixed asset turnover ratio suggests that Integra Lifesciences is effectively utilizing its fixed assets to generate sales.

On the other hand, the total asset turnover ratio has also been consistent, ranging from 0.40 to 0.42. This ratio indicates that the company is generating revenue in relation to its total assets. A higher total asset turnover ratio signifies that Integra Lifesciences is efficiently generating sales from its total asset base.

Overall, the company's long-term activity ratios suggest that Integra Lifesciences Holdings Corp is effectively managing and utilizing its assets to generate revenue consistently. The stable performance of these ratios over the quarters indicates operational efficiency and effective asset utilization in the company's business operations.